BAVARIAN NORDIC Reported Earnings

BAVARIAN NORDIC (BVNRY) reported earnings of $0.46 per share on revenue of $316.47 million for the . . Revenue grew 26.02% on a year-over-year basis.

Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company's product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark.